Supplementary 5: Ruxolitinib outcomes

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ruxolitinib | | | | | | | | | | |
| Indication | Birth Outcomes | | | | | Congenital Malformation | Exposure Until | | | |
|  | Live Birth | Spontaneous Abortion | Still Birth | Ectopic Pregnancy | Elective Termination |  | First | Second | Third | Ongoing |
| RHL | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|  | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0 | 0.0% | 0.0% | 0.0% | 100.0% |
| Myelofibrosis | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| Total | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| 2 | 50.0% | 0.0% | 0.0% | 0.0% | 50.0% | 0.0% | 50.0% | 0.0% | 0.0% | 50.0% |